Fair Value Measurements (Details) - Recurring - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2016	Dec. 31, 2015
Financial instruments measured at fair value on a recurring basis
Warrant consideration	[1]	$ 6,000	$ 6,000
Total		183,278	178,320
Contingent Consideration Under Tax Receivables Agreement
Financial instruments measured at fair value on a recurring basis
Contingent consideration	[2]	156,145	149,620
Contingent Consideration For Achievement Of Specified Average Adjusted Ebitda
Financial instruments measured at fair value on a recurring basis
Contingent consideration	[3]	21,133	22,700
Level 2
Financial instruments measured at fair value on a recurring basis
Warrant consideration	[1]	6,000	6,000
Total		6,000	6,000
Level 3
Financial instruments measured at fair value on a recurring basis
Total		177,278	172,320
Level 3 | Contingent Consideration Under Tax Receivables Agreement
Financial instruments measured at fair value on a recurring basis
Contingent consideration	[2]	$ 156,145	149,620
Tax effect rate (as a percent)		37.00%
Level 3 | Contingent Consideration For Achievement Of Specified Average Adjusted Ebitda
Financial instruments measured at fair value on a recurring basis
Contingent consideration	[3]	$ 21,133	$ 22,700

[1] These liabilities relate to warrants to purchase the Company's common stock and future obligations to deliver additional such warrants in relation to the Business Combination. The inputs used in the fair value measurement were directly observable quoted prices for identical assets in an inactive market.

[2] The fair value of the tax amortization benefit contingency is measured using an income approach based on the Company's best estimate of the undiscounted cash payments to be made, tax effected at 37% and discounted to present value utilizing an appropriate market discount rate. The valuation technique used did not change during the three months ended March 31, 2016.

[3] The fair value of the deferred acquisition payment is measured using a Black-Scholes option pricing model and based on the Company's best estimate of the Company's average Business EBITDA, as defined in the Purchase Agreement, over the two year period from January 1, 2016 to December 31, 2017. The valuation technique used did not change during the three months ended March 31, 2016.